ATE458500T1 - Pharmazeutische verbindung zur behandlung von lokal fortgeschrittenem primär inoperablen pankreaskarzinom (lapc). - Google Patents
Pharmazeutische verbindung zur behandlung von lokal fortgeschrittenem primär inoperablen pankreaskarzinom (lapc).Info
- Publication number
- ATE458500T1 ATE458500T1 AT04795677T AT04795677T ATE458500T1 AT E458500 T1 ATE458500 T1 AT E458500T1 AT 04795677 T AT04795677 T AT 04795677T AT 04795677 T AT04795677 T AT 04795677T AT E458500 T1 ATE458500 T1 AT E458500T1
- Authority
- AT
- Austria
- Prior art keywords
- human
- dose
- lapc
- treatment
- pharmaceutical compound
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/525—Tumour necrosis factor [TNF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
- C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Wood Science & Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Toxicology (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Plant Pathology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US52012703P | 2003-11-14 | 2003-11-14 | |
PCT/US2004/034544 WO2005051432A1 (en) | 2003-11-14 | 2004-10-20 | Therapeutic regimen for treating cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE458500T1 true ATE458500T1 (de) | 2010-03-15 |
Family
ID=34632749
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT04795677T ATE458500T1 (de) | 2003-11-14 | 2004-10-20 | Pharmazeutische verbindung zur behandlung von lokal fortgeschrittenem primär inoperablen pankreaskarzinom (lapc). |
Country Status (8)
Country | Link |
---|---|
US (3) | US20060257369A1 (de) |
EP (2) | EP2168603A1 (de) |
JP (1) | JP2007511507A (de) |
AT (1) | ATE458500T1 (de) |
CA (1) | CA2545815A1 (de) |
DE (1) | DE602004025726D1 (de) |
ES (1) | ES2340038T3 (de) |
WO (1) | WO2005051432A1 (de) |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2557164A1 (de) | 2003-02-18 | 2013-02-13 | Kevin M. Slawin | Induzierte Aktivierung ein dendritischen Zellen |
US20060127443A1 (en) * | 2004-12-09 | 2006-06-15 | Helmus Michael N | Medical devices having vapor deposited nanoporous coatings for controlled therapeutic agent delivery |
US20070224235A1 (en) | 2006-03-24 | 2007-09-27 | Barron Tenney | Medical devices having nanoporous coatings for controlled therapeutic agent delivery |
US8187620B2 (en) | 2006-03-27 | 2012-05-29 | Boston Scientific Scimed, Inc. | Medical devices comprising a porous metal oxide or metal material and a polymer coating for delivering therapeutic agents |
US8815275B2 (en) | 2006-06-28 | 2014-08-26 | Boston Scientific Scimed, Inc. | Coatings for medical devices comprising a therapeutic agent and a metallic material |
JP2009542359A (ja) | 2006-06-29 | 2009-12-03 | ボストン サイエンティフィック リミテッド | 選択的被覆部を備えた医療装置 |
ATE508708T1 (de) | 2006-09-14 | 2011-05-15 | Boston Scient Ltd | Medizinprodukte mit wirkstofffreisetzender beschichtung |
US20080294236A1 (en) * | 2007-05-23 | 2008-11-27 | Boston Scientific Scimed, Inc. | Endoprosthesis with Select Ceramic and Polymer Coatings |
US8431149B2 (en) * | 2007-03-01 | 2013-04-30 | Boston Scientific Scimed, Inc. | Coated medical devices for abluminal drug delivery |
US8815273B2 (en) | 2007-07-27 | 2014-08-26 | Boston Scientific Scimed, Inc. | Drug eluting medical devices having porous layers |
WO2009018340A2 (en) | 2007-07-31 | 2009-02-05 | Boston Scientific Scimed, Inc. | Medical device coating by laser cladding |
EP2185103B1 (de) | 2007-08-03 | 2014-02-12 | Boston Scientific Scimed, Inc. | Überzug für ein medizinprodukt mit vergrösserter oberfläche |
US20090118818A1 (en) * | 2007-11-02 | 2009-05-07 | Boston Scientific Scimed, Inc. | Endoprosthesis with coating |
US20090118812A1 (en) * | 2007-11-02 | 2009-05-07 | Boston Scientific Scimed, Inc. | Endoprosthesis coating |
US8216632B2 (en) | 2007-11-02 | 2012-07-10 | Boston Scientific Scimed, Inc. | Endoprosthesis coating |
US20090118821A1 (en) * | 2007-11-02 | 2009-05-07 | Boston Scientific Scimed, Inc. | Endoprosthesis with porous reservoir and non-polymer diffusion layer |
US20090118813A1 (en) * | 2007-11-02 | 2009-05-07 | Torsten Scheuermann | Nano-patterned implant surfaces |
JP5581311B2 (ja) | 2008-04-22 | 2014-08-27 | ボストン サイエンティフィック サイムド,インコーポレイテッド | 無機材料のコーティングを有する医療デバイス及びその製造方法 |
WO2009132176A2 (en) | 2008-04-24 | 2009-10-29 | Boston Scientific Scimed, Inc. | Medical devices having inorganic particle layers |
US8449603B2 (en) * | 2008-06-18 | 2013-05-28 | Boston Scientific Scimed, Inc. | Endoprosthesis coating |
EP2331680B1 (de) | 2008-09-22 | 2017-05-03 | Baylor College Of Medicine | Verfahren und zusammensetzungen zur erzeugung einer immunreaktion mittels cd40-induktion sowie strukturerkennungsrezeptoradaptern |
EP2367535B1 (de) * | 2008-12-02 | 2017-02-22 | Biocompatibles Uk Ltd. | Behandlung von bauchspeicheldrüsentumoren |
US8231980B2 (en) | 2008-12-03 | 2012-07-31 | Boston Scientific Scimed, Inc. | Medical implants including iridium oxide |
US8287937B2 (en) | 2009-04-24 | 2012-10-16 | Boston Scientific Scimed, Inc. | Endoprosthese |
WO2011074564A1 (ja) * | 2009-12-15 | 2011-06-23 | タカラバイオ株式会社 | アデノウイルスベクターの製造方法 |
RU2012148706A (ru) * | 2010-04-16 | 2014-05-27 | Новартис Аг | Комбинация органичемких соединений |
JP5975983B2 (ja) * | 2010-04-16 | 2016-08-23 | ベリカム ファーマシューティカルズ, インコーポレイテッド | 固形腫瘍を処置するための方法 |
US9142017B2 (en) * | 2010-12-29 | 2015-09-22 | Koninklijke Philips N.V. | TNM classification using image overlays |
JP2018517759A (ja) * | 2015-06-19 | 2018-07-05 | シン−ナット プロダクツ エンタープライズ エルエルシー | カルボプラチンを含む組成物及び用途 |
AU2019362029A1 (en) * | 2018-10-19 | 2021-04-01 | University Of Rochester | Immune modulators in combination with radiation treatment for advanced pancreatic cancer |
EP4096781A1 (de) | 2020-01-28 | 2022-12-07 | RefleXion Medical, Inc. | Gemeinsame optimierung von radionuklid und externer strahlentherapie |
Family Cites Families (68)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5288852A (en) * | 1984-03-06 | 1994-02-22 | Dainippon Pharmaceutical Co., Ltd. | Human tumor necrosis factor polypeptides |
US4879226A (en) | 1984-04-06 | 1989-11-07 | Asahi Kasei Kogyo Kabushiki Kaisha | Novel human physiologically active polypeptide |
US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
US4863457A (en) | 1986-11-24 | 1989-09-05 | Lee David A | Drug delivery device |
US4932412A (en) | 1986-12-18 | 1990-06-12 | Immunomedics, Inc. | Intraoperative and endoscopic tumor detection and therapy |
US5206152A (en) | 1988-04-08 | 1993-04-27 | Arch Development Corporation | Cloning and expression of early growth regulatory protein genes |
US5763209A (en) * | 1988-09-26 | 1998-06-09 | Arch Development Corporation | Methods and materials relating to the functional domains of DNA binding proteins |
US5698531A (en) * | 1989-03-31 | 1997-12-16 | The Regents Of The University Of Michigan | Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor |
ATE199398T1 (de) * | 1989-10-24 | 2001-03-15 | Chiron Corp | Sekretion vom mit gamma-interferon signalpeptid gebundenen humänen protein |
CA2055168A1 (en) * | 1990-11-21 | 1992-05-22 | Walter Fiers | Tnf-muteins |
US6605712B1 (en) | 1990-12-20 | 2003-08-12 | Arch Development Corporation | Gene transcription and ionizing radiation: methods and compositions |
CA2098849C (en) * | 1990-12-20 | 2007-07-10 | Ralph R. Weichselbaum | Control of gene expression by ionizing radiation |
US5378475A (en) | 1991-02-21 | 1995-01-03 | University Of Kentucky Research Foundation | Sustained release drug delivery devices |
US5358866A (en) * | 1991-07-03 | 1994-10-25 | The United States Of America As Represented By The Department Of Health And Human Services | Cytosine deaminase negative selection system for gene transfer techniques and therapies |
GB9223084D0 (en) | 1992-11-04 | 1992-12-16 | Imp Cancer Res Tech | Compounds to target cells |
US5968735A (en) * | 1992-11-12 | 1999-10-19 | Max Delbruck-Centrum Fur Molekular Medizin Berlin | Vector for the expression of therapy-relevant genes |
US5801029A (en) * | 1993-02-16 | 1998-09-01 | Onyx Pharmaceuticals, Inc. | Cytopathic viruses for therapy and prophylaxis of neoplasia |
DK0667912T3 (da) | 1993-07-13 | 2008-11-10 | Centelion | Defekte adenovirusvektorer og anvendelse heraf i genterapi |
US5543328A (en) | 1993-08-13 | 1996-08-06 | Genetic Therapy, Inc. | Adenoviruses having modified fiber proteins |
US5631236A (en) * | 1993-08-26 | 1997-05-20 | Baylor College Of Medicine | Gene therapy for solid tumors, using a DNA sequence encoding HSV-Tk or VZV-Tk |
US5443505A (en) | 1993-11-15 | 1995-08-22 | Oculex Pharmaceuticals, Inc. | Biocompatible ocular implants |
WO1995016772A1 (en) | 1993-12-14 | 1995-06-22 | Cornell Research Foundation, Inc. | Adenovirus gene expression system |
US5641755A (en) * | 1994-02-04 | 1997-06-24 | Arch Development Corp. | Regulation of x-ray mediated gene expression |
US5571797A (en) * | 1994-05-11 | 1996-11-05 | Arch Development Corporation | Method of inducing gene expression by ionizing radiation |
US5851806A (en) | 1994-06-10 | 1998-12-22 | Genvec, Inc. | Complementary adenoviral systems and cell lines |
DE69535178T2 (de) | 1994-06-10 | 2006-12-14 | Genvec, Inc. | Adenoviren-vektor systeme und zelllinien |
US5846782A (en) | 1995-11-28 | 1998-12-08 | Genvec, Inc. | Targeting adenovirus with use of constrained peptide motifs |
US6465253B1 (en) | 1994-09-08 | 2002-10-15 | Genvec, Inc. | Vectors and methods for gene transfer to cells |
US5962311A (en) | 1994-09-08 | 1999-10-05 | Genvec, Inc. | Short-shafted adenoviral fiber and its use |
US5965541A (en) | 1995-11-28 | 1999-10-12 | Genvec, Inc. | Vectors and methods for gene transfer to cells |
US5559099A (en) | 1994-09-08 | 1996-09-24 | Genvec, Inc. | Penton base protein and methods of using same |
WO1997020051A2 (en) | 1995-11-28 | 1997-06-05 | Genvec, Inc. | Vectors and methods for gene transfer to cells |
US5998205A (en) | 1994-11-28 | 1999-12-07 | Genetic Therapy, Inc. | Vectors for tissue-specific replication |
IL116816A (en) | 1995-01-20 | 2003-05-29 | Rhone Poulenc Rorer Sa | Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof |
US5962424A (en) * | 1995-02-21 | 1999-10-05 | Arch Development Corporation | Methods and compositions for targeting selectins |
US6127525A (en) | 1995-02-21 | 2000-10-03 | Cornell Research Foundation, Inc. | Chimeric adenoviral coat protein and methods of using same |
US5770442A (en) | 1995-02-21 | 1998-06-23 | Cornell Research Foundation, Inc. | Chimeric adenoviral fiber protein and methods of using same |
US6281010B1 (en) * | 1995-06-05 | 2001-08-28 | The Trustees Of The University Of Pennsylvania | Adenovirus gene therapy vehicle and cell line |
US5993800A (en) * | 1995-06-05 | 1999-11-30 | Bristol-Myers Squibb Company | Methods for prolonging the expression of a heterologous gene of interest using soluble CTLA4 molecules and an antiCD40 ligand |
JP4051416B2 (ja) | 1995-06-15 | 2008-02-27 | クルーセル ホランド ベスローテン フェンノートシャップ | 遺伝子治療に使用されるヒト組換えアデノウイルス用のパッケージングシステム |
US6254862B1 (en) * | 1997-03-03 | 2001-07-03 | Calydon, Inc. | Adenovirus vectors specific for cells expressing alpha-fetoprotein and methods of use thereof |
US5837511A (en) | 1995-10-02 | 1998-11-17 | Cornell Research Foundation, Inc. | Non-group C adenoviral vectors |
EP0866721A4 (de) | 1995-12-08 | 2003-06-04 | Univ Alabama Birmingham Res Fo | Adenovirale zielvektoren |
WO1997039135A1 (en) * | 1996-04-17 | 1997-10-23 | Board Of Regents, The University Of Texas System | Enhanced expression of transgenes |
AU3583797A (en) | 1996-06-28 | 1998-01-21 | Regents Of The University Of California, The | Enhancement of cancer cell death |
US5922315A (en) | 1997-01-24 | 1999-07-13 | Genetic Therapy, Inc. | Adenoviruses having altered hexon proteins |
US5849561A (en) | 1997-05-22 | 1998-12-15 | Cornell Research Foundation, Inc. | Method for the production of non-group C adenoviral vectors |
BR9809173A (pt) | 1997-05-28 | 2000-08-01 | Genvec Inc | Adenovìrus alternativamente direcionados |
ATE256196T1 (de) | 1997-06-09 | 2003-12-15 | Genvec Inc | Chimäre vektoren, die die verpackungsregion eines phagengenoms und einen teil des genoms eines eukaryontischen virus enthalten |
US5944106A (en) | 1997-08-06 | 1999-08-31 | Halliburton Energy Services, Inc. | Well treating fluids and methods |
DE69831417T2 (de) | 1997-09-23 | 2006-06-22 | Genvec, Inc. | Duale selektionkassette und sie enthaltende plasmide |
US6899870B1 (en) * | 1998-03-11 | 2005-05-31 | Board Of Regents, The University Of Texas System | Induction of apoptic or cytotoxic gene expression by adenoviral mediated gene codelivery |
SK15682000A3 (sk) | 1998-04-22 | 2001-05-10 | Genvec, Inc. | Účinné čistenie adenovírusu |
US6113913A (en) | 1998-06-26 | 2000-09-05 | Genvec, Inc. | Recombinant adenovirus |
US5965358A (en) | 1998-08-26 | 1999-10-12 | Genvec, Inc. | Method for assessing the relative purity of viral gene transfer vector stocks |
WO2000015823A1 (en) | 1998-09-11 | 2000-03-23 | Genvec, Inc. | Alternatively targeted adenovirus |
US6225289B1 (en) | 1998-12-10 | 2001-05-01 | Genvec, Inc. | Methods and compositions for preserving adenoviral vectors |
US6337338B1 (en) * | 1998-12-15 | 2002-01-08 | Telik, Inc. | Heteroaryl-aryl ureas as IGF-1 receptor antagonists |
DE60038624T2 (de) | 1999-10-07 | 2009-06-10 | Aquilar-Cordova, Carlos, Estuardo, Newton | Methoden zur behandlung von festen tumoren und metastasen mit gentherapie |
AU2001234981A1 (en) | 2000-02-09 | 2001-08-20 | Genvec, Inc. | Adenoviral capsid containing chimeric protein ix |
US6168941B1 (en) | 2000-04-07 | 2001-01-02 | Genvec, Inc. | Method of producing adenoviral vector stocks |
EP1301612A2 (de) | 2000-05-31 | 2003-04-16 | Genvec, Inc. | Verfahren und zusammenfassung zur zielrichtung von adenoviralen vektoren |
US6579522B1 (en) | 2000-06-27 | 2003-06-17 | Genvec, Inc. | Replication deficient adenoviral TNF vector |
US6447995B1 (en) | 2000-10-04 | 2002-09-10 | Genvec, Inc. | Utilizing intrinsic fluorescence to detect adenovirus |
ATE541937T1 (de) | 2001-04-06 | 2012-02-15 | Univ Chicago | Chemotherapeutische einleitung der egr-1-promoter-aktivität in gentherapie |
US20030087438A1 (en) | 2001-11-02 | 2003-05-08 | Genvec, Inc. | E1-revertant-free adenoviral composition |
US20030086903A1 (en) * | 2001-11-02 | 2003-05-08 | Genvec, Inc. | Therapeutic regimen for treating cancer |
US20030153065A1 (en) | 2002-01-14 | 2003-08-14 | Genvec, Inc. | Composition and method for maintaining non-enveloped viral vectors |
-
2004
- 2004-10-20 EP EP10150655A patent/EP2168603A1/de not_active Withdrawn
- 2004-10-20 EP EP04795677A patent/EP1687032B1/de not_active Not-in-force
- 2004-10-20 ES ES04795677T patent/ES2340038T3/es active Active
- 2004-10-20 WO PCT/US2004/034544 patent/WO2005051432A1/en active Search and Examination
- 2004-10-20 JP JP2006539520A patent/JP2007511507A/ja active Pending
- 2004-10-20 DE DE602004025726T patent/DE602004025726D1/de active Active
- 2004-10-20 AT AT04795677T patent/ATE458500T1/de not_active IP Right Cessation
- 2004-10-20 CA CA002545815A patent/CA2545815A1/en not_active Abandoned
-
2006
- 2006-05-12 US US11/432,943 patent/US20060257369A1/en not_active Abandoned
-
2010
- 2010-09-01 US US12/873,737 patent/US20110034752A1/en not_active Abandoned
-
2011
- 2011-12-29 US US13/339,536 patent/US20120123186A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20110034752A1 (en) | 2011-02-10 |
US20120123186A1 (en) | 2012-05-17 |
CA2545815A1 (en) | 2005-06-09 |
EP1687032B1 (de) | 2010-02-24 |
DE602004025726D1 (de) | 2010-04-08 |
ES2340038T3 (es) | 2010-05-28 |
US20060257369A1 (en) | 2006-11-16 |
WO2005051432A1 (en) | 2005-06-09 |
EP1687032A1 (de) | 2006-08-09 |
JP2007511507A (ja) | 2007-05-10 |
EP2168603A1 (de) | 2010-03-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE458500T1 (de) | Pharmazeutische verbindung zur behandlung von lokal fortgeschrittenem primär inoperablen pankreaskarzinom (lapc). | |
DE60230807D1 (de) | Behandlung von sarkom bei menschen mit adenovirus-vektor tnf-alpha | |
ATE307608T1 (de) | Kombination von doctaxel und rhumab her2 zür krebsbehandlung | |
TW200518752A (en) | Combinations of drugs for the treatment of neoplasms | |
CY1106601T1 (el) | Χρηση του παραγωγου κουιναζολινης zd6474 συνδυασμενου με γκεμσιταμπινη και προαιρετικα με ιοντιζουσα ακτινοβολια στη θεραπεια του καρκινου | |
NO20050450L (no) | Kombinasjon av ZD6474, en inhibitor av vaskulaer endotelial vekst faktor reseptor, med radioterapi ved behandling av kreft | |
DE60324427D1 (de) | Verfahren zur modulation der tubulindeacetylase-aktivität | |
SG166775A1 (en) | Combinations and modes of administration of therapeutic agents and combination therapy | |
WO2001066103A3 (en) | Treatment of neoplasms by inhalation of carboplatin | |
WO2004006842A3 (en) | Combinations of drugs for the treatment of neoplasms | |
CY1106259T1 (el) | Συνδυασμενη θepαπεια που πepιλαμβανει zd6474 κι ενα ταξανιο | |
ATE197670T1 (de) | Parenterales busulfan zur behandlung von malignen krankheiten | |
DE60039730D1 (de) | Genetisch manipulierte Herpesviren zur Behandlung von Tumoren | |
BR0207443A (pt) | Método e forma de dosagem para o tratamento de tumores pela administração de tegafur, uracila, ácido folìnico, paclitaxel e carboplatina | |
BR9813318A (pt) | Processo de tratamento de tumores e degeneração macular em paciente humano ou veterinário, composição farmacêutica para tratamento de tumores e degeneração macular em um paciente humano ou veterinário | |
ATE330590T1 (de) | Pharmazeutische zusammensetzungen enthaltend tetrac sowie deren verwendungsverfahren | |
ATE453402T1 (de) | Verwendung von serp-1 in kombination mit einem immunosuppressor zur behandlung von arthritis | |
EA200801731A1 (ru) | Составы и способы лечения тробмоцитемии | |
ATE485818T1 (de) | Zusammensetzungen aus ezetimib und verfahren zur behandlung von mit cholesterin zusammenhängenden gutartigen und bösartigen tumoren | |
WO2004007676A3 (en) | Combination therapy for the treatment of neoplasms | |
DE602004024221D1 (de) | Behandlung von entzündlichen darmerkrankungen mit 2-methylen-19-nor-vitamin d verbindungen | |
ATE281841T1 (de) | Verfahren zur herstellung von mikania extrakten enthaltend mikanolide und dihydromikanolide und verwendung in der behandlung proliferativer erkrankungen | |
WO2004056971A3 (en) | Methods of treatment of a bcl-2 disorder using bcl-2 antisense oligomers | |
WO2023164455A3 (en) | Compositions and methods to modulate the immune system | |
ATE302011T1 (de) | PONAZURIL ZUR BEHANDLUNG VON DURCH COCCIDIA NEUROLOGISCHEN UND ßABORTIGENICß VERURSACHTEN ERKRANKUNGEN |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification |
Ref document number: 1687032 Country of ref document: EP |
|
REN | Ceased due to non-payment of the annual fee |